

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Original) A liposome encapsulating a water-soluble substance in an internal cavity thereof, which has a particle size of 300 nm or less and contains a triglycerol.
2. (Currently Amended) ~~The~~ ~~A~~ liposome ~~encapsulating a water-soluble substance in an internal cavity thereof~~ according to claim 1, which has a particle size of 200 nm or less ~~and contains a triglycerol~~.
3. (Currently Amended) The liposome according to claim 1 ~~or 2~~, wherein an encapsulation rate of the water-soluble compound in the internal cavity is 60% or higher.
4. (Currently Amended) The liposome according to claim 1 ~~or 2~~, wherein an encapsulation rate of the water-soluble compound in the internal cavity is 70% or higher.
5. (Currently Amended) The liposome according to ~~any one of claims 1 to 4~~ claim 1, wherein the water-soluble substance is a water-soluble low molecular weight compound, a protein, a nucleic acid, a polysaccharide, and/or an indicator.
6. (Currently Amended) The liposome according to ~~any one of claims 1 to 4~~ claim 1, wherein the water-soluble substance is a water-soluble low molecular weight compound and a polysaccharide.
7. (Currently Amended) The liposome according to ~~any one of claims 1 to 4~~ claim 1, wherein the water-soluble substance is a water-soluble low molecular weight compound.

8. (Currently Amended) The liposome according to ~~any one of claims 5 to 7~~ claim 5, wherein the water-soluble low molecular weight compound is nedaplatin, cisplatin, carboplatin, gemcitabine, or Ara-C.
9. (Currently Amended) The liposome according to claim 5 ~~or 6~~, wherein the polysaccharide is a chitosan derivative, or a polysaccharide having carboxyl group.
10. (Original) The liposome according to claim 9, wherein the polysaccharide having carboxyl group is carboxymethylcellulose, hyaluronic acid, chondroitin, or chondroitin sulfate.
11. (Currently Amended) The liposome according to ~~any one of claims 1 to 10~~ claim 1, wherein the triglycerol is triolein.
12. (Currently Amended) The liposome according to ~~any one of claims 1 to 11~~ claim 1, which contains a ligand and/or a water-soluble synthetic polymer.
13. (Currently Amended) The liposome according to ~~any one of claims 1 to 11~~ claim 1, which contains a ligand.
14. (Currently Amended) The liposome according to claim 12 ~~or 13~~, wherein the ligand binds to a target cell or a target molecule.
15. (Currently Amended) The liposome according to ~~any one of claims 12 to 14~~ claim 12, wherein the ligand is an antibody or an antibody fragment.
16. (Original) The liposome according to claim 12, wherein the water-soluble synthetic polymer is selected from the group consisting of polyalkylene glycol, polylactic acid, polyglycolic acid, polyvinylpyrrolidone, and a copolymer of vinylpyrrolidone and maleic anhydride.

17. (Currently Amended) The liposome according to ~~claims 12 or 16~~ claim 12, wherein the water-soluble synthetic polymer is polyalkylene glycol.

18. (Currently Amended) The liposome according to claim 16 ~~or 17~~, wherein the polyalkylene glycol is polyethylene glycol.

19. (Currently Amended) The liposome according to ~~any one of claims 12 to 18~~ claim 12, wherein the ligand and/or the water-soluble synthetic polymer binds only to an external surface of the liposome.

20. (Currently Amended) A pharmaceutical composition containing the liposome according to ~~any one of claims 1 to 19~~ claim 1.

21. (Currently Amended) An agent for diagnosis and/or therapeutic treatment of a cancer, which comprises the liposome according to ~~any one of claims 1 to 19~~ claim 1.